Hemanth Kumar
@drhemanthmd1
Followers
953
Following
5K
Media
67
Statuses
1K
Medical Oncologist. Cure, Heal, Care & Comfort. Consultant at Mangalore Institute of Oncology, Mangalore
Mangalore, India
Joined June 2019
RT @MatthewKurianMD: I wrote for #ASCOConnection about the duality of oncology—the quiet heaviness of being both oncologist and dad. The we….
lnkd.in
This link will take you to a page that’s not on LinkedIn
0
10
0
RT @SuyogCancer: 🚨 Just out in NEJM: #KEYNOTE689 💉🧠.Periop #pembrolizumab (neoadj + adj) + surgery + RT/CRT improves EFS in resectable LA-#….
0
40
0
RT @samdoc_mamc: Pleased to share Phase 2 trial results for low-dose regorafenib in relapsed synovial sarcoma. N=25, 76% previously expose….
0
15
0
RT @VincentRK: Photo of the year for myeloma: .Cilta-cel in multi-drug refractory disease. From Jagannath, @PlasmaCellPete et al @JCO_ASCO….
0
39
0
RT @NicoGagelmann: Cilta-cel shows potential for CURE in RRMM❗️. In the CARTITUDE-1 trial, a single infusion of cilta-cel delivered remarka….
0
6
0
RT @dr_yakupergun: Post #ASCO25 thoughts on the DESTINY-Breast09 trial:. T-DXd + pertuzumab extended mPFS to 40.7 months in 1st-line HER2+….
0
7
0
RT @drmpk91: CHALLENGE.👤 Who: Colon cancer survivors post-surgery.🏃 What: Exercise.🕒 How: Brisk walk 30–45 min, 3–4x/week for 3 yrs.⏱️ When….
0
4
0
RT @SuyogCancer: Most awaited data for #ASCO25 DESTINY-Breast09.1L T-DXd + P 💥 vs THP in HER2+ mBC.🧪 PFS (INV):.40.7 mo vs 20.7 mo.HR 0.49….
0
11
0
RT @ASCO: 5th Plenary #ASCO25: #MATTERHORN Ph III, Durvalumab + FLOT—>✂️—>Durva vs NeoAdj FLOT in resectable GEJ/Gastric Ca. - 2yr EFS 67%….
0
47
0
RT @drmpk91: Phase 2 Trials on Induction Chemoimmunotherapy, Radiation, and Consolidation IO in Stage III EGFR–Wild-Type NSCLC.Source: http….
0
3
0
RT @KrishanJethwa: 🚨DESTINY GASTRIC-04🚨.M1 Her2+ Gastric Cancer, 2nd line therapy.🔎Trastuzumab Deruxtecan vs Ramucirumab + Paclitaxel.✅⬆️OS….
0
14
0
RT @dr_yakupergun: #ASCO25. Oral paclitaxel (DHP107) vs IV paclitaxel in HER2– mBC. PFS ➡️ 10.0 vs 8.5 mo.OS ➡️ 32.9 vs 32.5 mo.ORR ➡️ 45.8….
0
56
0
RT @YAbdouMD: ASCENT-04: SG+ pembro vs chemo+ pembro for PD-L1+ mTNBC in 1st line setting . ⬆️mPFS 11.2m vs 7.8m.⬆️mDOR 16.5 vs 9.2m.⬆️ OR….
0
7
0
RT @OncBrothers: @OncoAlert @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD This is by far the most impo….
0
1
0
RT @SuyogCancer: Infact we have 6 regimens now in advanced HCC . Nivo plus IPI data ( checkmate 9DW ) updated for comparison @OncoAlert ht….
0
22
0
RT @VincentRK: The fascinating story of Thalidomide: how this most notorious drug on the planet, banned in the 1960s, made an incredible co….
0
175
0
RT @dr_yakupergun: #ESMOBreast25. Recent Advances In Treatment For Hr+ Her2- Breast Cancer. from Dr. @stolaney1 wonderful presentation👇. #….
0
71
0
RT @Dr_ElvinaA: Watch & Wait in rectal cancer: @JCO_ASCO study:.Distant mets in local regrowth pts = 22.8%.vs. 10.2% in TME pts (P≤.001)….
0
34
0
RT @QuantumOnc: Dr Akhil Santhosh reviewed all the newer drugs in solid oncology and taught the budding oncologist. eGurukul series taking….
0
3
0